Form 4: Baker Bros. Advisors Report Changes in Beneficial Ownership of Incyte Corp (INCY)

Baker Bros. Advisors LP reports changes in beneficial ownership of Incyte Corp stock due to the exercise of stock options by Julian C. Baker, a director of Incyte, with the resulting shares allocated to affiliated funds.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of Incyte Corp (INCY) common stock.
• The reported transaction involves the exercise of 15,000 non-qualified stock options at a price of $49.01 per share by Julian C. Baker, a director of Incyte.
• The stock options were initially granted to Julian C. Baker for his service on the board.
• The common stock received upon exercise of these options is allocated to affiliated funds, including 667, L.P. and Baker Brothers Life Sciences, L.P.
• After the transaction, the total indirectly held shares by Baker Bros. entities is 33,462,981.
• Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the shares held by the funds.
• The filing also clarifies the relationships between the various Baker Bros. entities and their roles in investment and voting power over the securities.
• Julian C. Baker directly holds 278,773 shares of common stock.
• Felix J. Baker directly holds 281,190 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions and ownership details.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a major shareholder and director, which is common in the biopharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for insiders of publicly traded companies, including those in the biotechnology sector like Incyte.
• Baker Bros. Advisors is a well-known investment firm specializing in life sciences, and their holdings in Incyte are significant.
• Similar filings are regularly made by directors and major shareholders of companies like Gilead Sciences, Amgen, and Regeneron, reflecting stock option exercises, grants, and other transactions.

Stakeholder Impact

• The transaction itself has minimal direct impact on stakeholders.
• The disclosure provides transparency to shareholders regarding insider transactions and ownership structure.

Key Dates